Targeted Therapy

UC Researchers Target Hsp70 to Counter Pancreatic Cancer Immunosuppression With Preclinical Nanovesicle Therapy

An AACR presentation on Sept. 28 signals a push toward clinical testing following peer-reviewed preclinical work.